Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.

@article{Geus2017NeoadjuvantTV,
  title={Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.},
  author={Susanna W L de Geus and Mariam F. Eskander and Lindsay A. Bliss and Gyulnara G. Kasumova and Sing Chau Ng and Mark P. Callery and Jennifer Tseng},
  journal={Surgery},
  year={2017},
  volume={161 3},
  pages={
          592-601
        }
}
BACKGROUND Neoadjuvant therapy is an emerging paradigm in pancreatic cancer care; however, its role for resectable disease remains controversial in the absence of conclusive randomized controlled trials. The purpose of the present study is to assess the impact of neoadjuvant therapy on survival in resected pancreatic cancer patients by clinical stage. METHODS A retrospective cohort study using the National Cancer Data Base from 2004 to 2012 including nonmetastatic pancreatic adenocarcinoma… CONTINUE READING
9
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Optimizing the outcomes of pancreatic cancer surgery

Oliver Strobel, John P Neoptolemos, Dirk Jäger, Markus W. Büchler
  • Nature Reviews Clinical Oncology
  • 2018

Recent Advances in Pancreatic Cancer Surgery

  • Current Treatment Options in Gastroenterology
  • 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 48 REFERENCES

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.

  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2014
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL